Diabetes Drug Boosts Chemo's Effectiveness
May 08, 2007
May 7, 2007 (HealthDay News)—The diabetes drug rosiglitazone (brand name Avandia) dramatically increases the potency of platinum-based cancer drugs, U.S. researchers report.
In research with mice, scientists at the Dana-Farber Cancer Institute in Boston found that combining a platinum chemotherapy agent with rosiglitazone was as much as three times more effective at halting or shrinking tumors than using either of the drugs alone. The findings are published in the May issue of the journal Cancer Cell.
If the same results can be achieved in humans, this combination therapy may help improve control of ovarian, lung and other cancers routinely treated with platinum-based chemotherapy, according to the researchers, who note that tumors eventually become resistant to platinum-based chemotherapy. The results suggest that this combination treatment may extend the use of platinum-based chemotherapy to other cancers which have previously not responded to this kind of chemotherapy, they add.
"There's still a huge gulf between these experiments and human cancers. But it's worked in every animal model of cancer we've looked at, and I think there's a fair chance it will help people," senior author Bruce Spiegelman says. The Dana-Farber team is developing plans for initial human clinical trials, which may begin this year.
For more information about chemotherapy, visit The American Cancer Society.
<< Back
May 08, 2007
May 7, 2007 (HealthDay News)—The diabetes drug rosiglitazone (brand name Avandia) dramatically increases the potency of platinum-based cancer drugs, U.S. researchers report.
In research with mice, scientists at the Dana-Farber Cancer Institute in Boston found that combining a platinum chemotherapy agent with rosiglitazone was as much as three times more effective at halting or shrinking tumors than using either of the drugs alone. The findings are published in the May issue of the journal Cancer Cell.
If the same results can be achieved in humans, this combination therapy may help improve control of ovarian, lung and other cancers routinely treated with platinum-based chemotherapy, according to the researchers, who note that tumors eventually become resistant to platinum-based chemotherapy. The results suggest that this combination treatment may extend the use of platinum-based chemotherapy to other cancers which have previously not responded to this kind of chemotherapy, they add.
"There's still a huge gulf between these experiments and human cancers. But it's worked in every animal model of cancer we've looked at, and I think there's a fair chance it will help people," senior author Bruce Spiegelman says. The Dana-Farber team is developing plans for initial human clinical trials, which may begin this year.
For more information about chemotherapy, visit The American Cancer Society.
<< Back
